OncoMatch/Clinical Trials/NCT06390319
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Is NCT06390319 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for t-cell acute lymphoblastic leukemia.
Treatment: Dexamethasone · Vincristine · Daunorubicin · Calaspargase pegol · Dasatinib · Venetoclax · Bortezomib · Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) · Cyclophosphamide · Cytarabine · Mercaptopurine · Nelarabine · Methotrexate · Thioguanine — This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end of induction MRD-negative rate is higher in patients with ETP or near-ETP ALL treated with venetoclax compared to similar patients treated with 4-drug induction on AALL1231. Secondary Objectives * To assess the event free and overall survival of patients treated with this therapy. * To compare grade 4 toxicities, event-free survival (EFS) and overall survival (OS) of patients treated with this therapy in induction and reinduction to toxicities of similar patients treated on TOT17.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Prior therapy
Cannot have received: chemotherapy
Exception: therapy given on or allowed by initiall
Lab requirements
Kidney function
GFR ≥ 50 mL/min/1.73m^2 using Bedside Schwartz equation OR creatinine below or equal to age/sex-specific maximum
Liver function
Direct bilirubin ≤ 1.5x ULN for age; ALT ≤ 5x ULN for age
Direct bilirubin ≤ 1.5x the upper limit of normal for age; Alanine aminotransferase (ALT) ≤ 5x the upper limit of normal for age; Calculated glomerular filtration rate (GFR) ≥ 50 mL/min/1.73m^2 using the Bedside Schwartz equation OR creatinine below or equal to the maximum defined below
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rady Children's Hospital · San Diego, California
- Saint Francis Children's Hospital · Tulsa, Oklahoma
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify